SEARCH

SEARCH BY CITATION

References

  • 1
    Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33: 14491461, 1990
  • 2
    Felson DT, Anderson JJ, Meenan RF: Comparing second line drugs for RA: efficacy/toxicity tradeoffs (abstract). Arthritis Rheum 34 (suppl 9): S53, 1991
  • 3
    Weinstein A, Marlowe S, Korn J, Farouhar F: Lowdose methotrexate treatment of rheumatoid arthritis: long-term observations. Am J Med 79: 331337, 1985
  • 4
    Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS: Long-term prospective trial of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 35: 129137, 1992
  • 5
    Fehlauer CS, Carson CW, Cannon GW, Ward JR, Samuelson CO, Williams HJ, Clegg DO: Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study. J Rheumatol 16: 307312, 1989
  • 6
    Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA: Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 17: 16281635, 1990
  • 7
    Weinblatt M, Walker AM, Funch D, Dreyer NA, AlarcónG, Klippel J, Kremer J, Lee R, Tolman K: Serious liver disease in methotrexate-treated rheumatoid arthritis patients (abstract). Arthritis Rheum 34 (suppl 9): S49, 1991
  • 8
    Phillips CA, Cera PJ, Mangan TF, Newman ED: Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 19: 229233, 1992
  • 9
    Kremer JM, Lee RG, Tolman KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 32: 121127, 1989
  • 10
    Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 309: 10941104, 1983
  • 11
    Shiroky J, Neville C: Leucovorin for methotrexate induced elevations in liver transaminases (abstract). Arthritis Rheum 33 (suppl 5): R34, 1990
  • 12
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315324, 1988
  • 13
    Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140: 659662, 1949
  • 14
    The Cooperating Clinics Committee of the American Rheumatism Association: A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 8: 302334, 1965
  • 15
    Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 23: 137145, 1980
  • 16
    Kremer JM, Galivan J, Streckfuss A, Kamen B: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29: 832835, 1986
  • 17
    Hanrahan PS, Russell AS: Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 15: 10781080, 1988
  • 18
    Buckley LM, Vacek PM, Cooper SM: Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 17: 11581161, 1990
  • 19
    Tishler M, Caspi D, Fishel B, Yaron M: The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 31: 906908, 1988
  • 20
    Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 50: 913914, 1991
  • 21
    Shiroky J, Allegra C, Inghirami G, Chabner B, Yarboro C, Klippel JH: High dose intravenous methotrexate with leucovorin rescue in rheumatoid arthritis. J Rheumatol 15: 251255, 1988
  • 22
    Shiroky JB, Neville C, Skelton JD: High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 19: 247251, 1992
  • 23
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 918, 1990
  • 24
    Hanrahan PS, Scrivens GA, Russell AS: Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy, and radiological progression. Br J Rheumatol 28: 147153, 1989
  • 25
    Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 35: 138145, 1992